Which of the following is the goal of monitoring peak and trough levels during antibacterial therapy?
Keep the serum drug level within the therapeutic margin
increase the therapeutic effect of the drug by gradually decreasing the drug dose
Provide maximum physical comfort to the patient
Treat the main disorder with no psychological distress to the patient
The Correct Answer is A
A. Keep the serum drug level within the therapeutic margin:
This is the correct goal of monitoring peak and trough levels during antibacterial therapy. The therapeutic margin refers to the range of drug concentrations in the bloodstream that achieves optimal therapeutic effects while avoiding toxicity. By monitoring peak and trough levels, healthcare providers can adjust the dosing regimen to maintain drug levels within this therapeutic margin.
B. Increase the therapeutic effect of the drug by gradually decreasing the drug dose:
This statement is incorrect. Monitoring peak and trough levels is not about increasing the therapeutic effect of the drug by gradually decreasing the drug dose. Instead, it's about ensuring that the drug levels are maintained within the appropriate therapeutic range to achieve optimal efficacy without causing adverse effects.
C. Provide maximum physical comfort to the patient:
Monitoring peak and trough levels is not primarily aimed at providing physical comfort to the patient. While optimizing drug therapy can contribute to improved clinical outcomes and patient well-being, the goal of monitoring these levels is specifically related to achieving therapeutic drug concentrations.
D. Treat the main disorder with no psychological distress to the patient:
This statement is unrelated to the goal of monitoring peak and trough levels during antibacterial therapy. While psychological distress may be a consideration in patient care, the primary goal of monitoring drug levels is to ensure therapeutic efficacy and safety.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is C
Explanation
A. Ibuprofen:
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to relieve pain and reduce inflammation. There are no significant interactions reported between erythromycin and ibuprofen.
B. Lasix (Furosemide):
Lasix is a diuretic medication used to treat fluid retention (edema) and high blood pressure. There are no significant interactions reported between erythromycin and furosemide.
C. Lovastatin:
Lovastatin is a statin medication used to lower cholesterol levels. Erythromycin can increase the levels of lovastatin in the blood by inhibiting its metabolism through the CYP3A4 enzyme. This can lead to an increased risk of statin-related side effects, including muscle pain and weakness, and in rare cases, rhabdomyolysis.
D. Lisinopril:
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure and heart failure. There are no significant interactions reported between erythromycin and lisinopril.
Correct Answer is A
Explanation
- Do not have to demonstrate effectiveness:
This statement is generally true under DSHEA regulations. Unlike pharmaceutical drugs, dietary supplements are not required to undergo rigorous testing to demonstrate their effectiveness in treating, preventing, or curing specific health conditions before they are marketed. However, manufacturers are prohibited from making unsubstantiated claims about the effectiveness of their products.
B. Are determined to be safe before being placed on the market:
Under DSHEA regulations, dietary supplement manufacturers are responsible for ensuring the safety of their products before they are marketed. However, unlike pharmaceutical drugs, dietary supplements do not undergo premarket approval by the Food and Drug Administration (FDA) to verify their safety and efficacy. Instead, manufacturers are required to notify the FDA of their intent to market a new dietary ingredient (NDI) and provide evidence of the ingredient’s safety.
C. Are checked for label accuracy:
The FDA regulates dietary supplements to ensure that their labels are accurate and truthful. However, the extent of label accuracy checking varies, and the FDA does not routinely test every dietary supplement product on the market. Instead, the FDA relies on postmarket surveillance, consumer complaints, and other mechanisms to identify and address inaccuracies or violations of labeling regulations.
D. Are tested prior to marketing:
Unlike pharmaceutical drugs, dietary supplements are not required to undergo premarket testing to demonstrate their safety or efficacy before they are marketed. While manufacturers are responsible for ensuring the safety of their products, there is no formal premarket testing requirement under DSHEA regulations.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
